Psychedelics closer to commercialization; Compass far and away the leader
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Analyst https://seekingalpha.com/author/alexander-carchidi?source=ie_podcast:psychedelics_closer_to_commercialization_compass_leader discusses positive news coming out of psychedelic space (1:00). Recent earnings show companies moving closer to commercialization (3:35). https://seekingalpha.com/symbol/CYBN?source=ie_podcast:psychedelics_closer_to_commercialization_compass_leader and Atai developments; clinical studies and regulatory relief (5:25)....
show moreShow Notes:
Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatment
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
COMPASS Pathways Q1 2024 Earnings Call Transcript
Episode transcripts
For full access to analyst ratings, stock quant scores as well as dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Register for Seeking Alpha's Investing Summit (with your podcast discount code!)
Information
Author | Seeking Alpha |
Organization | Seeking Alpha |
Website | seekingalpha.com |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Comments